BETTER THERAPEUTICS, INC.

(BTTX)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
1.690 USD   -6.11%
06/16Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
BU
06/13BETTER THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/09Better Therapeutics to Participate in Cowen's Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/22/2022 06/23/2022 06/24/2022 06/27/2022 06/28/2022 Date
1.84(c) 1.88(c) 1.87(c) 1.8(c) 1.69 Last
1 639 544 746 894 444 527 299 100 293 291 Volume
+23.49% +2.17% -0.53% -3.74% -6.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -40,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,97x
Yield 2022 -
Sales 2023 3,76 M - -
Net income 2023 -126 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,40x
Yield 2023 -
Capitalization 39,9 M 39,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 10,6x
Nbr of Employees 44
Free-Float 44,9%
More Financials
Company
Better Therapeutics, Inc, is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive-behavioral therapy to address the root causes of cardiometabolic diseases. The Company's Nutritional Cognitive Behavioral Therapy (Nutritional CBT) is a novel form of behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It targets the... 
More about the company
Ratings of Better Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about BETTER THERAPEUTICS, INC.
06/16Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
BU
06/13BETTER THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/09Better Therapeutics to Participate in Cowen's Unlocking the Value of Digital Prescripti..
BU
06/08Better Therapeutics Issued US Patent for Features of Prescription Digital Therapeutics ..
MT
06/08Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Pr..
BU
06/07Better Therapeutics Hires Former Myovant Sciences CFO Frank Karbe as Chief Executive
MT
06/07BETTER THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/07Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
BU
06/07Better Therapeutics, Inc. Appoints Frank Karbe as President and as Member of the Board ..
CI
06/07Better Therapeutics Appoints Frank Karbe as Chief Executive Officer Starting July 5, 20..
CI
05/25Top Premarket Decliners
MT
05/19Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabe..
BU
05/13BETTER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/13Better Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/13Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on..
BU
More news
News in other languages on BETTER THERAPEUTICS, INC.
06/08Better Therapeutics a obtenu un brevet américain pour les caractéristiques de la platef..
06/07Better Therapeutics engage l'ancien directeur financier de Myovant Sciences, Frank Karb..
06/07Better Therapeutics, Inc. nomme Frank Karbe comme président et membre du conseil d'admi..
06/07Better Therapeutics nomme Frank Karbe au poste de directeur général à compter du 5 juil..
05/13Better Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ma..
More news
Analyst Recommendations on BETTER THERAPEUTICS, INC.
More recommendations
Chart BETTER THERAPEUTICS, INC.
Duration : Period :
Better Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BETTER THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,69 $
Average target price 17,00 $
Spread / Average Target 906%
EPS Revisions
Managers and Directors
Kevin J. Appelbaum President, Chief Executive Officer & Director
Mark Heinen Chief Financial Officer & Head-Finance
David P. Perry Executive Chairman
Mark Berman Chief Medical Officer
Andres Camacho Senior Vice President-Technology
Sector and Competitors
1st jan.Capi. (M$)
BETTER THERAPEUTICS, INC.-59.78%44
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-11.87%18 371